The presentations cover a range of topics, from new preclinical studies further elucidating the roles of the soluble protein target CCL24 and Chemomab's CCL24 neutralizing antibody CM-101 in fibro-inflammatory disease, to novel translational research designed to support the ongoing clinical development of CM-101 for primary sclerosing cholangitis, a rare and often fatal fibrotic liver disease. The presentations will be made available and described in greater detail post embargo.
Date:
Format: Poster presentation: Attenuating liver fibrosis and inflammation: blocking CCL24 inhibits recruitment of hepatic stellate cells, monocytes and neutrophils and modulates hepatic stellate cell activation
Presenter: Prof.
Information: 2024 Chemotactic Cytokines Conference GRC
Date:
Time:
Format: Poster presentation: Ex-vivo translational assay of hepatic stellate cells using patient-derived serum characterizes the anti-fibrotic activity of CM-101
Presenter:
Session: Poster - Fibrosis/Stellate cell biology, Abstract #380
Date:
Time:
Format: Poster presentation: Machine learning-driven identification of serum protein signature for primary sclerosing cholangitis and enhanced liver fibrosis score
Presenter:
Session: Immune-mediated and cholestatic: Experimental and pathophysiology, Abstract #1032
Date:June 7, 2024
Time:
Format: Poster Tour: Ex-vivo translational assay of hepatic stellate cells using patient-derived serum characterizes the anti-fibrotic activity of CM-101
Presenter:
Session: Fibrosis/Stellate Cell Biology Poster Tour, Abstract #380
Location: Basic Science Track Hub
Information:
In addition, Chemomab Corporate Development will be in
About
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from three clinical trials of CM-101 in patients, including a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis has completed patient enrollment, with topline data expected midyear 2024. Chemomab's CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open
Contact:
Tel: +1 917-355-9234
Email: barbara.lindheim@chemomab.com
(C) 2024 Electronic News Publishing, source